Meeting in Valencia of Spanish researchers on Limb-girdle Muscular Dystrophy 1F/D2

Last Friday, September 20, we participated in the meeting that took place at the University of Valencia together with two of the research teams that we finance and that are led by scientists José Alcamí Pertejo (Instituto de Salud Carlos III) and Rubén Artero (University of Valencia). In addition, Professor Juan José Vílchez, currently honorary professor at the University of Valencia and researcher at Ciberer, also attended.

These groups are part of the international research alliance that we at Conquistando Escalones lead and fund, but, as we published, since 2022 they have the support of the Ministry of Science and Innovation. Specifically, the Spanish teams are focused on the project entitled “Translational research on Transportin-3. A key protein in the genesis of LGMDD2 muscular dystrophy that confers resistance to HIV infection (TRANS3-HIV-MUSA)» with which it is intended to exploit the synergies between both fields of research to generate new molecular, cellular and animal models, including a murine model of LGMDD2, with which to study pathogenesis mechanisms. An essential component of the collaborative project is to develop drug discovery programs through high-throughput screening and the validation of candidates in the different in vitro and in vivo models previously generated.

These meetings are very fruitful since they bring together the work and progress of the research groups. Preliminary results are also shared, doubts for joint work and the next steps are specified for the goal of using drugs in patients.

Along these lines, the president of the Conquistando Escalones Association, Abrahán Guirao, wanted to highlight “the pride” that comes with working with world leaders in various scientific fields, as well as how “exciting” it is to be a direct witness of these meetings, which reflect the arduous task they carry out in laboratories.

Guirao wanted to conclude by pointing out that “we have no doubt that the treatments for our disease will arrive and are getting closer, as always we will give you details of the advances.”[/vc_column_text][/vc_column][/vc_row]